Intravascular immunity as a key to systemic vasculitis: A work in progress, gaining momentum

Clinical and Experimental Immunology

Volumn 175, Issue 2, 2014, Pages 150-166

  Ramirez, G A ^a   Maugeri, N ^a   Sabbadini, M G ^a   Rovere Querini, P ^a   Manfredi, A A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Intravascular immunity; Pathogenesis; Thrombosis; Treatment; Vasculitis; Vessel inflammation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BLISIBIMOD; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; GLUCOCORTICOID; INFLAMMASOME; INFLIXIMAB; MEPOLIZUMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TREBANANIB;

ARTERITIS; ARTICLE; ASSOCIATION; B LYMPHOCYTE; BEHCET DISEASE; DRUG MEGADOSE; EOSINOPHILIC GRANULOMA; ERYTHEMA NODOSUM; EXTRAVASATION; HUMAN; INNATE IMMUNITY; LEUKOCYTE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SYSTEMIC VASCULITIS; T LYMPHOCYTE; THROMBOSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

INTRAVASCULAR IMMUNITY; PATHOGENESIS; THROMBOSIS; TREATMENT; VASCULITIS; VESSEL INFLAMMATION;

B-LYMPHOCYTES; BACTERIAL INFECTIONS; BLOOD VESSELS; C-REACTIVE PROTEIN; HUMANS; INFLAMMASOMES; SERUM AMYLOID P-COMPONENT; SYSTEMIC VASCULITIS; T-LYMPHOCYTES; THROMBOSIS;

EID: 84891613605     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12223     Document Type: Article

References (240)

1. Luqmani RA, Suppiah R, Grayson PC, Merkel PA, Watts R. Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS). Clin Exp Immunol 2011; 164 (Suppl. 1):11-13.
2. Jennette JC, Falk RJ, Bacon PA etal. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1-11.
3. Langford C. Takayasu's arteritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, eds. Rheumatology. Oxford: Elsevier, 2010:1567-1573.
4. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349:160-169.
5. Chauhan SK, Singh M, Nityanand S. Reactivity of gamma/delta T cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum 2007; 56:2798-2802.
6. Vaglio A, Pipitone N, Salvarani C. Chronic periaortitis: a large-vessel vasculitis? Curr Opin Rheumatol 2011; 23:1-6.
7. Grayson PC, Maksimowicz-McKinnon K, Clark TM etal. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis 2012; 71:1329-1334.
8. Vaglio A, Catanoso MG, Spaggiari L etal. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013; 65:2469-2475. doi: 10.1002/art.38032.
9. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Balt) 2009; 88:221-226.
10. Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr Opin Rheumatol 2013; 25:19-25.
11. Hwang J, Kim SJ, Bang OY etal. Ischemic stroke in Takayasu's arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012; 8:109-115.
12. Mukhtyar C, Guillevin L, Cid MC etal. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68:318-323.
13. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E. Treatment of refractory Takayasu arteritis with tocilizumab: seven Italian patients from a single referral center. J Rheumatol 2013.
14. Mekinian A, Neel A, Sibilia J etal. Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxf) 2012; 51:882-886.
15. Burns JC. Kawasaki disease. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, eds. Rheumatology. Oxford: Elsevier, 2010:1583-1586.
16. Chan M, Luqmani R. Pharmacotherapy of vasculitis. Expert Opin Pharmacother 2009; 10:1273-1289.
17. Breunis WB, Davila S, Shimizu C etal. Disruption of vascular homeostasis in patients with Kawasaki disease: involvement of vascular endothelial growth factor and angiopoietins. Arthritis Rheum 2012; 64:306-315.
18. Burns JC, Best BM, Mejias A etal. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008; 153:833-838.
19. Burns JC, Song Y, Bujold M etal. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013; 174:337-344.
20. Langford CA. Vasculitis. J Allergy Clin Immunol 2010; 125:S216-225.
21. Ishiguro N, Kawashima M. Cutaneous polyarteritis nodosa: a report of 16 cases with clinical and histopathological analysis and a review of the published work. J Dermatol 2010; 37:85-93.
22. Lidar M, Lipschitz N, Langevitz P, Shoenfeld Y. The infectious etiology of vasculitis. Autoimmunity 2009; 42:432-438.
23. de Menthon M, Mahr A. Treating polyarteritis nodosa: current state of the art. Clin Exp Rheumatol 2011; 29:S110-116.
24. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol 2013; 8:139-160.
25. Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schonlein purpura. Kidney Int 2010; 78:495-502.
26. Quartuccio L, Isola M, Corazza L etal. Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2012; 30:S48-52.
27. Fabrizi F, Dixit V, Messa P. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. J Med Virol 2013; 85:1019-1027.
28. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008; 111:5334-5341.
29. Savage CO. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Clin Exp Immunol 2011; 164 (Suppl. 1):23-26.
30. Kettritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. Clin Exp Immunol 2012; 169:220-228.
31. Kallenberg CG, Heeringa P. Complement is crucial in the pathogenesis of ANCA-associated vasculitis. Kidney Int 2013; 83:16-18.
32. Jennette JC. Nomenclature and classification of vasculitis: lessons learned from granulomatosis with polyangiitis (Wegener's granulomatosis). Clin Exp Immunol 2011; 164 (Suppl. 1):7-10.
33. Kallenberg CG. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011; 70 (Suppl. 1):i59-63.
34. Fujimoto S, Watts RA, Kobayashi S etal. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxf) 2011; 50:1916-1920.
35. Sinico RA, Bottero P, Guillevin L. Antineutrophil cytoplasmic autoantibodies and clinical phenotype in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2012; 130:1440. author reply, 1.
36. Vaglio A, Buzio C, Zwerina J. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): state of the art. Allergy 2013; 68:261-273.
37. Merkel PA, Lo GH, Holbrook JT etal. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142:620-626.
38. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564-567.
39. Suppiah R, Judge A, Batra R etal. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011; 63:588-596.
40. Gaffo AL. Thrombosis in vasculitis. Best Pract Res Clin Rheumatol 2013; 27:57-67.
41. Lyons PA, Rayner TF, Trivedi S etal. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367:214-223.
42. Holle JU, Gross WL. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev 2013; 12:483-486.
43. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Balt) 2011; 90:19-27.
44. Cohen P, Pagnoux C, Mahr A etal. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57:686-693.
45. Langford CA. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011; 164 (Suppl. 1):31-34.
46. Jones RB, Tervaert JW, Hauser T etal. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
47. Stone JH, Merkel PA, Spiera R etal. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
48. Specks U, Merkel PA, Seo P etal. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417-427.
49. Niles J. Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. Clin Exp Immunol 2011; 164 (Suppl. 1):27-30.
50. Guerry MJ, Brogan P, Bruce IN etal. Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxf) 2012; 51:634-643.
51. Luqmani R. Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol 2013; 9:127-132.
52. Dalvi SR, Yildirim R, Yazici Y. Behçet's syndrome. Drugs 2012; 72:2223-2241.
53. Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV, Kirazli S. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Intern Med 1996; 240:181-187.
54. Takeno M, Kariyone A, Yamashita N etal. Excessive function of peripheral blood neutrophils from patients with Behçet's disease and from HLA-B51 transgenic mice. Arthritis Rheum 1995; 38:426-433.
55. Caliskan M, Yilmaz S, Yildirim E etal. Endothelial functions are more severely impaired during active disease period in patients with Behçet's disease. Clin Rheumatol 2007; 26:1074-1078.
56. Remmers EF, Cosan F, Kirino Y etal. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42:698-702.
57. Mizuki N, Meguro A, Ota M etal. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010; 42:703-706.
58. Shimizu J, Takai K, Fujiwara N etal. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-gamma in patients with Behçet's disease. Clin Exp Immunol 2012; 168:68-74.
59. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behçet's disease. Autoimmun Rev 2012; 11:687-698.
60. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behçet's disease. Autoimmun Rev 2012; 11:699-704.
61. Kirino Y, Bertsias G, Ishigatsubo Y etal. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45:202-207.
62. Hatemi G, Silman A, Bang D etal. EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis 2008; 67:1656-1662.
63. Desbois AC, Wechsler B, Resche-Rigon M etal. Immunosuppressants reduce venous thrombosis relapse in Behçet's disease. Arthritis Rheum 2012; 64:2753-2760.
64. Hatemi G, Silman A, Bang D etal. Management of Behçet's disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet's disease. Ann Rheum Dis 2009; 68:1528-1534.
65. Hickey MJ, Kubes P. Intravascular immunity: the host-pathogen encounter in blood vessels. Nat Rev Immunol 2009; 9:364-375.
66. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158-173.
67. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM. Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 2008; 118:1276-1284.
68. Deng J, Ma-Krupa W, Gewirtz AT, Younge BR, Goronzy JJ, Weyand CM. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res 2009; 104:488-495.
69. Smith DD, Tan X, Raveendran VV, Tawfik O, Stechschulte DJ, Dileepan KN. Mast cell deficiency attenuates progression of atherosclerosis and hepatic steatosis in apolipoprotein E-null mice. Am J Physiol Heart Circ Physiol 2012; 302:H2612-2621.
70. Maugeri N, Rovere-Querini P, Evangelista V etal. An intense and short-lasting burst of neutrophil activation differentiates early acute myocardial infarction from systemic inflammatory syndromes. PLOS ONE 2012; 7:e39484.
71. Phillipson M, Kubes P. The neutrophil in vascular inflammation. Nat Med 2011; 17:1381-1390.
72. Maugeri N, Baldini M, Ramirez GA, Rovere-Querini P, Manfredi AA. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res 2012; 129:267-273.
73. Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010; 17:3-8.
74. Cloutier N, Tan S, Boudreau LH etal. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med 2013; 5:235-249.
75. Laffont B, Corduan A, Ple H etal. Activated platelets can deliver mRNA regulatory Ago2{middle dot}microRNA complexes to endothelial cells via microparticles. Blood 2013; 122:253-261.
76. Zhang Q, Raoof M, Chen Y etal. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-107.
77. Manfredi AA, Rovere-Querini P. The mitochondrion - a Trojan horse that kicks off inflammation? N Engl J Med 2010; 362:2132-2134.
78. McDonald B, Pittman K, Menezes GB etal. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330:362-366.
79. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13:159-175.
80. Niethammer P, Grabher C, Look AT, Mitchison TJ. A tissue-scale gradient of hydrogen peroxide mediates rapid wound detection in zebrafish. Nature 2009; 459:996-999.
81. Bosurgi L, Manfredi AA, Rovere-Querini P. Macrophages in injured skeletal muscle: a perpetuum mobile causing and limiting fibrosis, prompting or restricting resolution and regeneration. Front Immunol 2011; 2:62.
82. Proebstl D, Voisin MB, Woodfin A etal. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J Exp Med 2012; 209:1219-1234.
83. Wang S, Cao C, Chen Z etal. Pericytes regulate vascular basement membrane remodeling and govern neutrophil extravasation during inflammation. PLOS ONE 2012; 7:e45499.
84. Stark K, Eckart A, Haidari S etal. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs. Nat Immunol 2013; 14:41-51.
85. Alon R, Nourshargh S. Learning in motion: pericytes instruct migrating innate leukocytes. Nat Immunol 2013; 14:14-15.
86. Lerchenberger M, Uhl B, Stark K etal. Matrix metalloproteinases modulate ameboid-like migration of neutrophils through inflamed interstitial tissue. Blood 2013; 122:770-780.
87. Loof TG, Morgelin M, Johansson L etal. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118:2589-2598.
88. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013; 13:34-45.
89. Brinkmann V, Zychlinsky A. Neutrophil extracellular traps: is immunity the second function of chromatin? J Cell Biol 2012; 198:773-783.
90. Kessenbrock K, Krumbholz M, Schonermarck U etal. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623-625.
91. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32:1777-1783.
92. von Bruhl ML, Stark K, Steinhart A etal. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209:819-835.
93. Kambas K, Chrysanthopoulou A, Vassilopoulos D etal. Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease. Ann Rheum Dis 2013.
94. Coughlan AM, Freeley SJ, Robson MG. Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Immunol 2012; 169:229-237.
95. Clark SR, Ma AC, Tavener SA etal. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13:463-469.
96. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012; 12:324-333.
97. Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232-2238.
98. Nakazawa D, Tomaru U, Suzuki A etal. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64:3779-3787.
99. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. Front Immunol 2012; 3:380.
100. Sangaletti S, Tripodo C, Chiodoni C etal. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012; 120:3007-3018.
101. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol 2009; 156:395-404.
102. Tervaert JW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009; 156:377-385.
103. Ward JR, Wilson HL, Francis SE, Crossman DC, Sabroe I. Translational mini-review series on immunology of vascular disease: inflammation, infections and Toll-like receptors in cardiovascular disease. Clin Exp Immunol 2009; 156:386-394.
104. Kaiser M, Younge B, Bjornsson J, Goronzy JJ, Weyand CM. Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 1999; 155:765-774.
105. Weyand CM, Ma-Krupa W, Pryshchep O, Groschel S, Bernardino R, Goronzy JJ. Vascular dendritic cells in giant cell arteritis. Ann NY Acad Sci 2005; 1062:195-208.
106. Cid MC, Hernandez-Rodriguez J, Esteban MJ etal. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106:1664-1671.
107. Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z. Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 2011; 11:61-67.
108. Baldini M, Maugeri N, Ramirez GA etal. Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: relevance for recent optic nerve ischemia. Arthritis Rheum 2012; 64:854-865.
109. Baldini M, Manfredi AA, Maugeri N. Targeting platelet-neutrophil interactions in giant-cell arteritis. Curr Pharm Des 2013.
110. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011; 10:590-594.
111. Dallabrida SM, Ismail NS, Pravda EA etal. Integrin binding angiopoietin-1 monomers reduce cardiac hypertrophy. FASEB J 2008; 22:3010-3023.
112. Kugathasan L, Ray JB, Deng Y, Rezaei E, Dumont DJ, Stewart DJ. The angiopietin-1-Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic mice. J Exp Med 2009; 206:2221-2234.
113. Agrawal A, Matthay MA, Kangelaris KN etal. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013; 187:736-742.
114. Monach PA, Kumpers P, Lukasz A etal. Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis. PLOS ONE 2012; 7:e30197.
115. Trollope AF, Golledge J. Angiopoietins, abdominal aortic aneurysm and atherosclerosis. Atherosclerosis 2011; 214:237-243.
116. Tsuzuki T, Okada H, Cho H etal. Divergent regulation of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor by hypoxia and female sex steroids in human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol 2013; 168:95-101.
117. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res 2013; 319:1271-1280.
118. Choe JY, Park SH, Kim SK. Serum angiopoietin-1 level is increased in patients with Behcet's disease. Joint Bone Spine 2010; 77:340-344.
119. Scholz A, Lang V, Henschler R etal. Angiopoietin-2 promotes myeloid cell infiltration in a beta(2)-integrin-dependent manner. Blood 2011; 118:5050-5059.
120. David S, Kumpers P, Lukasz A, Kielstein JT, Haller H, Fliser D. Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens 2009; 27:1641-1647.
121. Kumpers P, David S, Haubitz M etal. The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus. Ann Rheum Dis 2009; 68:1638-1643.
122. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73:1649-1657.
123. Dunne JV, Keen KJ, Van Eeden SF. Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int 2013; 33:475-484.
124. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005; 117:69-80.
125. Karlan BY, Oza AM, Richardson GE etal. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30:362-371.
126. Manfredi AA, Rovere-Querini P, Bottazzi B, Garlanda C, Mantovani A. Pentraxins, humoral innate immunity and tissue injury. Curr Opin Immunol 2008; 20:538-544.
127. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28:157-183.
128. Jaillon S, Peri G, Delneste Y etal. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204:793-804.
129. Maugeri N, Rovere-Querini P, Slavich M etal. Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 2011; 187:970-979.
130. Deban L, Russo RC, Sironi M etal. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-334.
131. Fazzini F, Peri G, Doni A etal. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44:2841-2850.
132. van Rossum AP, Pas HH, Fazzini F etal. Abundance of the long pentraxin PTX3 at sites of leukocytoclastic lesions in patients with small-vessel vasculitis. Arthritis Rheum 2006; 54:986-991.
133. Rovere P, Peri G, Fazzini F etal. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000; 96:4300-4306.
134. Baruah P, Propato A, Dumitriu IE etal. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood 2006; 107:151-158.
135. van Rossum AP, Fazzini F, Limburg PC etal. The prototypic tissue pentraxin PTX3, in contrast to the short pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 2004; 50:2667-2674.
136. Ohlsson SM, Pettersson A, Ohlsson S etal. Phagocytosis of apoptotic cells by macrophages in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. Clin Exp Immunol 2012; 170:47-56.
137. Gout E, Moriscot C, Doni A etal. M-ficolin interacts with the long pentraxin PTX3: a novel case of cross-talk between soluble pattern-recognition molecules. J Immunol 2011; 186:5815-5822.
138. Ma YJ, Doni A, Romani L etal. Ficolin-1-PTX3 complex formation promotes clearance of altered self-cells and modulates IL-8 production. J Immunol 2013; 191:1324-1333.
139. Jylhava J, Haarala A, Kahonen M etal. Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 2011; 164:211-217.
140. Dagna L, Salvo F, Tiraboschi M etal. Pentraxin-3 as a marker of disease activity in Takayasu arteritis. Ann Intern Med 2011; 155:425-433.
141. Ievoli E, Lindstedt R, Inforzato A etal. Implication of the oligomeric state of the N-terminal PTX3 domain in cumulus matrix assembly. Matrix Biol 2011; 30:330-337.
142. Rusnati M, Camozzi M, Moroni E etal. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104:92-99.
143. Leali D, Inforzato A, Ronca R etal. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. Arterioscler Thromb Vasc Biol 2012; 32:696-703.
144. Moalli F, Paroni M, Veliz Rodriguez T etal. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol 2011; 186:5425-5434.
145. D'Angelo C, De Luca A, Zelante T etal. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 2009; 183:4609-4618.
146. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005; 52:642-650.
147. Presta M, Camozzi M, Salvatori G, Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11:723-738.
148. Camozzi M, Zacchigna S, Rusnati M etal. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005; 25:1837-1842.
149. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science 2009; 323:1683-1684.
150. Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res 2011; 343:189-199.
151. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012; 8:195-202.
152. Andrassy M, Volz HC, Riedle N etal. HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction. J Intern Med 2011; 270:245-253.
153. Maugeri N, Franchini S, Campana L etal. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity 2012; 45:584-587.
154. Yoshizaki A, Komura K, Iwata Y etal. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol 2009; 29:180-189.
155. Eguchi T, Nomura Y, Hashiguchi T etal. An elevated value of high mobility group box 1 is a potential marker for poor response to high-dose of intravenous immunoglobulin treatment in patients with Kawasaki syndrome. Pediatr Infect Dis J 2009; 28:339-341.
156. Hoshina T, Kusuhara K, Ikeda K, Mizuno Y, Saito M, Hara T. High mobility group box 1 (HMGB1) and macrophage migration inhibitory factor (MIF) in Kawasaki disease. Scand J Rheumatol 2008; 37:445-449.
157. Taira T, Matsuyama W, Mitsuyama H etal. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. Clin Exp Immunol 2007; 148:241-247.
158. Sato F, Maruyama S, Hayashi H etal. High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract 2008; 108:c194-201.
159. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis 2010; 69:1888-1889.
160. Henes FO, Chen Y, Bley TA etal. Correlation of serum level of high mobility group box 1 with the burden of granulomatous inflammation in granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2011; 70:1926-1929.
161. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: its role in vascular inflammation and atherosclerosis. Autoimmun Rev 2012; 11:909-917.
162. Bruchfeld A, Wendt M, Bratt J etal. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med 2011; 17:29-35.
163. Rovere-Querini P, Capobianco A, Scaffidi P etal. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5:825-830.
164. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220:35-46.
165. Vezzoli M, Castellani P, Corna G etal. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 2011; 15:2161-2174.
166. Menu P, Vince JE. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 2011; 166:1-15.
167. Mankan AK, Kubarenko A, Hornung V. Immunology in clinic review series; focus on autoinflammatory diseases: inflammasomes: mechanisms of activation. Clin Exp Immunol 2012; 167:369-381.
168. Sokolovska A, Becker CE, Ip WK etal. Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. Nat Immunol 2013; 14:543-553.
169. Dbouk HA, Uthman IW. An overview of familial Mediterranean fever with emphasis on pyrin and colchicine. J Med Liban 2008; 56:35-41.
170. Mansfield E, Chae JJ, Komarow HD etal. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001; 98:851-859.
171. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411-419.
172. Guarda G, Braun M, Staehli F etal. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011; 34:213-223.
173. Serrano A, Carmona FD, Castaneda S etal. Evidence of association of the NLRP1 gene with giant cell arteritis. Ann Rheum Dis 2013; 72:628-630.
174. Fury W, Tremoulet AH, Watson VE etal. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum Immunol 2010; 71:865-873.
175. Lee Y, Schulte DJ, Shimada K etal. Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation 2012; 125:1542-1550.
176. Liang L, Tan X, Zhou Q etal. IL-1beta triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet's disease. Invest Ophthalmol Vis Sci 2013; 54:402-414.
177. Ture-Ozdemir F, Tulunay A, Elbasi MO etal. Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behçet's disease. Rheumatology (Oxf) 2013; 52:800-805.
178. Botsios C, Sfriso P, Furlan A, Punzi L, Dinarello CA. Resistant Behçet's disease responsive to anakinra. Ann Intern Med 2008; 149:284-286.
179. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012; 71:1589-1591.
180. Hinze CH, Colbert RA. B-cell depletion in Wegener's granulomatosis. Clin Rev Allergy Immunol 2008; 34:372-379.
181. Scapini P, Carletto A, Nardelli B etal. Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseases. Blood 2005; 105:830-837.
182. Holden NJ, Williams JM, Morgan MD etal. ANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Ann Rheum Dis 2011; 70:2229-2233.
183. Lake-Bakaar G, Jacobson I, Talal A. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol 2012; 170:231-237.
184. Cerutti A, Cols M, Puga I. Activation of B cells by non-canonical helper signals. EMBO Rep 2012; 13:798-810.
185. Bunch DO, McGregor JG, Khandoobhai NB etal. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013; 8:382-391.
186. Terrier B, Joly F, Vazquez T etal. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. J Immunol 2011; 187:6550-6563.
187. Zhu Z, Li R, Li H, Zhou T, Davis RS. FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling. Proc Natl Acad Sci USA 2013; 110:E1282-1290.
188. Cacoub P, Terrier B, Saadoun D. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options. Presse Med 2013; 42 (4 Pt 2):523-527. doi: 10.1016/j.lpm.2013.01.011.
189. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:835-842.
190. Zaja F, De Vita S, Mazzaro C etal. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
191. Holle JU, Dubrau C, Herlyn K etal. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012; 71:327-333.
192. Aries PM, Hellmich B, Voswinkel J etal. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858.
193. Berden AE, Kallenberg CG, Savage CO etal. Cellular immunity in Wegener's granulomatosis: characterizing T lymphocytes. Arthritis Rheum 2009; 60:1578-1587.
194. Lamprecht P, Wieczorek S, Epplen JT, Ambrosch P, Kallenberg CG. Granuloma formation in ANCA-associated vasculitides. APMIS Suppl 2009; 127:32-36.
195. Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2830-2838.
196. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007; 56:2080-2091.
197. Tsurikisawa N, Saito H, Tsuburai T etal. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008; 122:610-616.
198. Jagiello P, Aries P, Arning L etal. The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. Arthritis Rheum 2005; 52:4039-4043.
199. Chen M, Kallenberg CG. ANCA-associated vasculitides - advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6:653-664.
200. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2008; 58:2196-2205.
201. Nogueira E, Hamour S, Sawant D etal. Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2010; 25:2209-2217.
202. Jakiela B, Sanak M, Szczeklik W etal. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 2011; 29:S23-34.
203. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Defining the human T helper 17 cell phenotype. Trends Immunol 2012; 33:505-512.
204. Chi W, Zhu X, Yang P etal. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. Invest Ophthalmol Vis Sci 2008; 49:3058-3064.
205. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-1057.
206. Brack A, Geisler A, Martinez-Taboada VM, Younge BR, Goronzy JJ, Weyand CM. Giant cell vasculitis is a T cell-dependent disease. Mol Med 1997; 3:530-543.
207. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121:906-915.
208. Weyand CM, Kaiser M, Yang H, Younge B, Goronzy JJ. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 2002; 46:457-466.
209. Narvaez J, Bernad B, Gomez-Vaquero C etal. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008; 26:S57-62.
210. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332-1337.
211. Accardo-Palumbo A, Giardina AR, Ciccia F etal. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behcet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther 2010; 12:R109.
212. Haregewoin A, Soman G, Hom RC, Finberg RW. Human gamma delta+ T cells respond to mycobacterial heat-shock protein. Nature 1989; 340:309-312.
213. Hirsh MI, Junger WG. Roles of heat shock proteins and gamma delta T cells in inflammation. Am J Respir Cell Mol Biol 2008; 39:509-513.
214. Ergun T, Ince U, Eksioglu-Demiralp E etal. HSP 60 expression in mucocutaneous lesions of Behçet's disease. J Am Acad Dermatol 2001; 45:904-909.
215. Hamzaoui K, Hamzaoui A, Hentati F etal. Phenotype and functional profile of T cells expressing gamma delta receptor from patients with active Behçet's disease. J Rheumatol 1994; 21:2301-2306.
216. Yasuoka H, Yamaguchi Y, Mizuki N, Nishida T, Kawakami Y, Kuwana M. Preferential activation of circulating CD8+ and gammadelta T cells in patients with active Behçet's disease and HLA-B51. Clin Exp Rheumatol 2008; 26:S59-63.
217. Ling E, Shubinsky G, Press J. Increased proportion of CD3+CD4-CD8- double-negative T cells in peripheral blood of children with Behçet's disease. Autoimmun Rev 2007; 6:237-240.
218. Kabelitz D, Fazio J, Adam-Klages S etal. Gammadelta T-cells: basic features and potential role in vasculitis. Clin Exp Rheumatol 2010; 28:104-109.
219. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65:1440-1448.
220. Flossmann O, Baslund B, Bruchfeld A etal. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009; 68:1125-1130.
221. Birck R, Warnatz K, Lorenz HM etal. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003; 14:440-447.
222. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis 2008; 67:1322-1327.
223. Schluns KS. Window of opportunity for daclizumab. Nat Med 2011; 17:545-547.
224. Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol 2013; 29:397-404.
225. Goldminz AM, Gottlieb AB. Ustekinumab for psoriasis and psoriatic arthritis. J Rheumatol Suppl 2012; 89:86-89.
226. Calderon R, Estrada S, Ramirez de la Piscina P etal. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis. Rev Esp Enferm Dig 2010; 102:145-146.
227. Maffei S, Di Renzo M, Santoro S, Puccetti L, Pasqui AL. Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 2009; 13:63-65.
228. Terrier B, Bieche I, Maisonobe T etal. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 2010; 116:4523-4531.
229. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341-343.
230. Hernandez-Rodriguez J, Segarra M, Vilardell C etal. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003; 107:2428-2434.
231. Hirano T, Ohguro N, Hohki S etal. A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012; 22:298-302.
232. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro- Behçet's disease, the first report. Clin Neurol Neurosurg 2012; 114:297-298.
233. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behçet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012; 30:S73-75.
234. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43:1041-1048.
235. Salvarani C, Magnani L, Catanoso M etal. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51:151-156.
236. Salvarani C, Magnani L, Catanoso MG etal. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012; 30:S90-93.
237. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58:1197-1200.
238. Unizony S, Stone JH, Stone JR. New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 2013; 25:3-9.
239. Geri G, Terrier B, Rosenzwajg M etal. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol 2011; 128:655-664.
240. Terrier B, Geri G, Chaara W etal. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012; 64:2001-2011.